What is the method of action of gefitinib in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Gefitinib represents a class of EGFR tyrosine kinase inhibitors (TKIs) that act intracellularly to block activation of the EGFR pathway. [150, 151]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!